These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20180625)

  • 1. Several hemagglutinins of same serotype for induction of broad immunity against influenza A virus antigenic drift variants: WO2008048984.
    Stech J
    Expert Opin Ther Pat; 2010 Mar; 20(3):447-50. PubMed ID: 20180625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccine: the challenge of antigenic drift.
    Carrat F; Flahault A
    Vaccine; 2007 Sep; 25(39-40):6852-62. PubMed ID: 17719149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
    Tamura S; Tanimoto T; Kurata T
    Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to influenza.
    Schild GC; Oxford JS; Virelizier JL
    Dev Biol Stand; 1975; 28():253-72. PubMed ID: 47824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pandemic preparedness: toward a universal influenza vaccine.
    Roose K; Fiers W; Saelens X
    Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccine--outmaneuvering antigenic shift and drift.
    Treanor J
    N Engl J Med; 2004 Jan; 350(3):218-20. PubMed ID: 14724300
    [No Abstract]   [Full Text] [Related]  

  • 11. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
    Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
    Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
    Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing perspective on immunization against influenza.
    Johansson BE; Brett IC
    Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
    Johansson BE; Kilbourne ED
    Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Universal influenza vaccine still far in the future].
    Rimmelzwaan GF; Osterhaus AD
    Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2305-7. PubMed ID: 10589217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antigenic relationship between influenza A (H3N2) strains circulating in Argentina and vaccine strains].
    Savy VL; Baumeister EG; Pontoriero AV
    Medicina (B Aires); 1999; 59(3):225-30. PubMed ID: 10451559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inter-species transmission of the influenza virus].
    Meulemans G
    Bull Mem Acad R Med Belg; 1999; 154(5-6):263-70; discussion 270-2. PubMed ID: 10687244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
    Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL
    J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
    Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
    J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.